Zealand Pharma: positive Phase 3 results in hypoglycemia
(CercleFinance.com) - Danish biotech firm Zealand Pharma said on Friday that the primary and key secondary endpoints of the first multinational Phase 3 clinical trial of dasiglucagon for the treatment of severe hypoglycemia have been met.
The main aim of this first Phase 3 trial has been to evaluate the immunogenicity of three single doses of dasiglucagon following
subcutaneous administration in 90 patients with type-1 diabetes.
The trial also evaluated safety and tolerability.
Shares in Zealand Pharma were up slightly (+0.2% at 96 Danish kronor)
after this announcement.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The main aim of this first Phase 3 trial has been to evaluate the immunogenicity of three single doses of dasiglucagon following
subcutaneous administration in 90 patients with type-1 diabetes.
The trial also evaluated safety and tolerability.
Shares in Zealand Pharma were up slightly (+0.2% at 96 Danish kronor)
after this announcement.
Copyright (c) 2018 CercleFinance.com. All rights reserved.